Enlighted Adds Workplace Contact Tracing Application to Its Building IoT Platform
Enlighted, the leading building IoT platform provider, expands its award-winning IoT technology with workplace digital contact tracing to help employees return safely to manufacturing facilities, pharmaceutical labs, offices and more. Safe provides digital contact history for employees who self-report testing positive for COVID-19 to help reduce the spread of infection, keep healthy employees safe and productive, and eliminate the tedious, expensive and error-prone manual contact tracing process for employers.
The solution prioritizes data privacy without the need for storing personal information. Employees are assigned alphanumeric ID badges while entering the workplace. When an employee self-reports their badge ID and a positive test result, administrators query the Safe application, identify other IDs this badge came in contact with and share the anonymous IDs. Employees carrying those badge IDs can self-identify their exposure.
The Enlighted solution provides employers with location and proximity data to identify who an infected employee came in contact with inside the workplace, for how long and what areas they visited. The data is used to inform employees who might be at risk of infection and also drives sanitization efforts in areas the infected employee utilized. The application’s dashboard provides information on contacts in the building to assist management in developing safer workplace strategies. Additionally, Safe identifies how many close contacts are happening in a time period and location to proactively manage risk.
Enlighted is in a unique position to provide proven safer workplace solutions for COVID-19 and beyond with its IoT technology already installed in 320 million square feet of buildings globally. Existing customers can simply add the Safe app to their IoT platform. New customers can install the Enlighted IoT system through sensors in LED lighting or through the new USB-powered surface sensor, which can be easily applied under desks or in conference rooms.
“The important role of IoT technology in buildings has been further magnified by the COVID-19 pandemic,” said Stefan Schwab, CEO of Enlighted, a Siemens company. “The Enlighted sensory system can now provide digital contact tracing. It also lays the foundation for future-proofed buildings ready to help us understand with real-time data the changing nature of our at-work experiences and meet challenges beyond COVID-19.”
Enlighted offers a suite of data-driven safer workplace solutions, assisting planners in preparing and executing physical distancing processes, enhanced sanitization and monitoring, occupancy limits and now contact tracing. The IoT platform also integrates through APIs with third-party systems to provide touchless entry, smart desk hoteling, conference room booking and more.
The Safe application is available immediately for new and existing Enlighted customers. Visit www.enlightedinc.com/contact-sales to talk with a sales representative or request a demonstration, or visit http://www.enlightedinc.com to learn about Enlighted’s full suite of workplace safety solutions.
ABOUT ENLIGHTED
Designed to change everything, Enlighted provides the world’s most advanced Building IoT Platform for leading commercial and healthcare organizations around the globe, with more than 320 million square feet of building space deployed to date. Founded in 2009 and headquartered in Silicon Valley, Enlighted was acquired in 2018 and is a wholly-owned subsidiary of Siemens Industry, Inc. as part of Siemens Smart Infrastructure. For more information about Enlighted, visit enlightedinc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005237/en/
Contact information
Ann Gargiulo
Ann.gargiulo@enlightedinc.com
408.593.3148
Jennifer Manocchio
Jennifer@sweeney.agency
910.685.1222
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owl Labs: 89% of European Companies Plan on Having a Hybrid Workforce Post-pandemic23.6.2021 02:01:00 EEST | Press release
Research conducted by Owl Labs, which polled 2000 business leaders* based in the UK, Germany, France, and the Nordics** shows that just 11% of business leaders expect their employees to return to the office full-time, indicating a more permanent shift to hybrid working. What’s more, the majority of European organisations (92%) are keen to explore progressive policies post-pandemic including introducing working from anywhere (42%), core working hours (39%), a four-day week (39%), and unlimited holiday (22%). When considering why employers are permanently moving to a more flexible work model, profitability plays an important role. Close to two-thirds (62%) of European business leaders reported that hybrid working makes companies more profitable with Enterprise businesses (1000+ employees) the most likely to think so (73%) versus small and medium-sized companies (55%). As businesses continue to adapt to working in a Covid-19 environment, over a third (39%) of European business leaders ant
Northleaf Appoints Shane Feeney to Lead and Expand Its Well-established Global Secondaries Business22.6.2021 21:00:00 EEST | Press release
Northleaf Capital Partners (Northleaf) today announced that Shane Feeney has joined the firm as Global Head of Secondaries, based in Toronto. In this role, Feeney will oversee all aspects of Northleaf’s secondaries program, building on the firm’s highly successful 18-year track record in global secondary investing and enhancing existing team capabilities as the secondaries market continues to expand rapidly. Feeney most recently served as Senior Managing Director & Global Head of Private Equity at CPP Investments, one of the world’s largest institutional investors with $497.2 billion in assets under management as of March 31, 2021. In this role, Feeney led the teams responsible for CPP Investments’ direct private equity, Asia private equity, private equity funds and secondaries investments. Under Feeney’s leadership, CPP Investments’ private equity program assets under management grew by approximately $73.6 billion. In fiscal 2021, CPP Investments’ private equity program generated a ne
SES Successfully Prices EUR 150 Million Tap of 2026 Eurobond22.6.2021 19:46:00 EEST | Press release
SES S.A. announced today the successful launch and pricing of a tap of its 1.625% Notes due 22 March 2026 in which it has agreed to sell incremental senior unsecured fixed rate notes for a total amount of EUR 150 million. The new notes were priced at 106.665% of their nominal value representing a credit spread of 47bps and a yield-to-maturity of 0.207%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005953/en/ SES Successfully Prices EUR 150 Million Tap of 2026 Eurobond (Photo: Business Wire) SES is rated Baa2 by Moody’s (with negative outlook) and BBB- by Standard & Poor’s (with stable outlook). Proceeds of the issuance will be used for general corporate purposes. BBVA, Deutsche Bank and IMI Intesa Sanpaolo acted as Joint Bookrunners. The settlement is scheduled for 29 June 2021 and application has been made for the notes to be listed on the Luxembourg Stock Exchange. The securities were placed with a broad range of i
Safic-Alcan Extends Its Distribution Agreement With PMC Organometallix to the African Continent22.6.2021 19:35:00 EEST | Press release
Safic-Alcan, a global specialty chemicals distributor, is pleased to announce the extension of its distribution agreement with PMC Organometallix Inc. to the African continent. PMC Organometallix, Inc., a wholly owned subsidiary of PMC Group, N.A., Inc. has expanded its distribution agreement with Safic-Alcan to include the African continent. Effective immediately, Safic-Alcan will serve as an authorized distributor of PMC Organometallix’s FASCAT® catalysts and fine chemicals. FASCAT® catalysts are inorganic and organometallic tin compounds providing optimal conversion and curing characteristics - making these organometallic materials essential in a wide variety of applications. FASCAT® catalysts are used in the manufacture of synthetic lubricants, monomeric and polymeric ester synthesis, automotive e-coat, crosslinking of siloxanes, urethanes and chemical intermediates. “Building on our successful partnership with Safic-Alcan in continental Europe, we are pleased to extend our collabo
In Celebration of World Rainforest Day, 33 Qualified Teams and 9 Judges Announced in $10M XPRIZE Competition to Improve Understandings and Preservation of the Planet’s Rainforests22.6.2021 19:24:00 EEST | Press release
XPRIZE, the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, officially announced today the teams moving forward in the $10M XPRIZE Rainforest aimed at improving our understanding of the rainforest ecosystem. Sponsored by Alana Foundation, the five-year XPRIZE Rainforest is a call-to-action to help save rainforests through the development of transformative, scalable, and affordable technology to autonomously survey and monitor biodiversity in real-time, leading to insights that communicate the health, well-being, and value of standing tropical rainforests. XPRIZE Rainforest is co-developing an inclusive framework throughout all stages of the competition that ensures competing teams co-design and co-create solutions with Indigenous Peoples and local communities as key stakeholders and not just beneficiaries. These 33 teams will now leverage existing and emerging technologies, such as robotics, remote sensing, data analysis, artificial
BourseInside, The New Media Platform That Finds Attractive Investments for Curious Investors22.6.2021 18:08:00 EEST | Press release
On the stock market, small caps continue to outperform. Since 1926, they have posted a performance of 12.1% per year, in contrast to 9.7% for large caps. And yet these so-called "small stocks" have been largely ignored by the stock market. They are rarely covered by analysts, shunned by the mainstream stock-market press and neglected by funds. Nevertheless, they are of great interest to investors, in particular those who have recently taken to investing in the stock market in order to grow their savings (16% increase in investors in 2020). For half of these newcomers, investing in the stock market gives them the opportunity to support the French economy by supporting the growth of our future champions and to channel their savings into a more sustainable and fairer model. In order to further strengthen this link between the French people and the development of our national companies, we decided to create BourseInside, the first web/TV/newsletter media platform, fully dedicated to listed
DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma22.6.2021 17:31:00 EEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the European Commission (EC) has granted marketing authorisation for the expanded use of DARZALEX®▼ (daratumumab) subcutaneous (SC) formulation in two new indications. The first authorisation of these new indications is for the use of daratumumab SC in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adults with newly diagnosed systemic light chain (AL) amyloidosis. This approval makes this daratumumab-based regimen the first approved therapy for AL amyloidosis in Europe. The second authorisation is for the use of daratumumab SC in combination with pomalidomide and dexamethasone (D-Pd) for the treatment of adults with multiple myeloma (MM) who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor, and have
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom